Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002230998 | SCV002508421 | uncertain significance | Short-rib thoracic dysplasia 8 with or without polydactyly | 2021-08-28 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 769 of the WDR60 protein (p.Glu769Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is present in population databases (rs193204571, ExAC 0.04%). This variant has been observed in individual(s) with short-rib thoracic dysplasia (PMID: 29068549, Invitae). ClinVar contains an entry for this variant (Variation ID: 446627). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Center for Personalized Medicine, |
RCV003156100 | SCV003845338 | likely pathogenic | See cases | 2022-12-21 | criteria provided, single submitter | clinical testing | |
Dan Cohn Lab, |
RCV000516105 | SCV000612033 | pathogenic | Jeune thoracic dystrophy | 2017-06-01 | no assertion criteria provided | research | |
Dan Cohn Lab, |
RCV001291411 | SCV000612034 | pathogenic | Asphyxiating thoracic dystrophy 3 | 2017-06-01 | no assertion criteria provided | research | |
University of Washington Center for Mendelian Genomics, |
RCV000516105 | SCV001479910 | likely pathogenic | Jeune thoracic dystrophy | no assertion criteria provided | research | ||
University of Washington Center for Mendelian Genomics, |
RCV001291411 | SCV001479911 | likely pathogenic | Asphyxiating thoracic dystrophy 3 | no assertion criteria provided | research | ||
Prevention |
RCV003915443 | SCV004738001 | likely pathogenic | DYNC2I1-related disorder | 2023-12-18 | no assertion criteria provided | clinical testing | The DYNC2I1 c.2305G>A variant is predicted to result in the amino acid substitution p.Glu769Lys. This variant has been reported in the homozygous and compound heterozygous state in two individuals affected with DYNC2I1-related disease (Table S2 ISDR Case # R04-477 and R91-028 in Zhang et al. 2018. PubMed ID: 29068549). At PreventionGenetics, we have observed this variant in the homozygous state in two affected patients. This variant is interpreted as pathogenic or likely pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/446627/). This variant is reported in 0.029% of alleles in individuals of Latino descent in gnomAD. Based on the available evidence, we classify this variant as likely pathogenic. |